The best time to take Vigabatrin (Ocoda) and daily medication recommendations
Vigabatrin (trade name: Sabril) is an oral anti-epileptic drug, mainly used for the treatment of refractory partial epilepsy and infantile spasms. It irreversibly inhibits γ-aminobutyric acid transaminase (GABA-T) and increases the level of the inhibitory neurotransmitter GABA in the brain, thereby reducing the frequency of epileptic seizures. Because of its unique mechanism of action, Vigabatrin is often used in patients who have responded poorly to other anti-epileptic drugs.
The taking time of Vigabatrin should be as fixed as possible to ensure stable blood concentration and improve efficacy. It is usually recommended to take it orally twice a day, once in the morning and once in the evening. For pediatric patients, doctors may adjust the dosage and medication interval based on weight and condition. Regular dosing times can help reduce flare-ups while reducing the risk of side effects.

The daily dose of Vigabatrin needs to be adjusted individually according to the doctor's advice. The conventional starting dose for adults is 1 to 3 grams per day, taken in two divided doses; the dose for children is calculated based on body weight, about 50mg per kilogram of body weight, and is gradually adjusted to the optimal therapeutic dose. Tablets should be swallowed whole, with a small amount of water, or with food if necessary to reduce gastrointestinal discomfort. Patients should strictly follow the doctor's instructions and should not increase or decrease the dosage or change the frequency of taking the medicine on their own.
While taking Vigabatrin, epileptic seizures and changes in vision should be regularly monitored because the drug may cause retinopathy and visual field defects. For long-term use, your doctor may recommend a vision or visual field test every6 months. At the same time, patients should return to the clinic on time, maintain regular medication, and record attacks so that doctors can evaluate the efficacy and adjust the dose to ensure safety and therapeutic effect.
Reference link:https://www.drugs.com
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)